2181 — Mabpharm Share News
0.000.00%
Last trade - 00:00- HK$1.57bn
- HK$1.82bn
- CNY646.10m
Brief: Mabpharm Announces Acceptance Of NDA Of Cmab007 (Omalizumab) By Nmpa
Brief: Mabpharm Posts HY Loss Attributable RMB 145.2 MLN
Brief: Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
HK-listed Mabpharm hits one-year high on new drug approval
Brief: Mabpharm Says Approval From NMPA On New Drug Application Of Cmab008 (Infliximab For Injection)
Brief: Mabpharm Says Unit Granted Kexing Bioproducts An Exclusive License For Development Of An Antibody
Brief: Mabpharm Ltd Posts FY Loss Attributable RMB184.6 Mln
Brief: Mabpharm Announces Acquisition Of CMAB807
Brief: Mabpharm Says Wang Hao Appointed As CEO
Brief: Mabpharm Says New Drug Application For CMAB008 Submitted In China